Efficacy during the LTE period. Values are % (n/N) (95% CI).
| Endpoint | Day 169 | Day 729 | Day 1261 | Day 1821 |
|---|---|---|---|---|
| No. patients, % (n/N) (95% CI) | ||||
| ACR20 | 80.1 (1087/1357) (78.0–82.2) | 82.0 (973/1187) (79.8–84.2) | 84.6 (904/1068) (82.5–86.8) | 84.6 (356/421) (81.1–88.0) |
| ACR50 | 53.2 (724/1362) (50.5–55.8) | 60.8 (720/1185) (58.0–63.5) | 62.9 (672/1069) (60.0–65.8) | 65.5 (277/423) (61.0–70.0) |
| ACR70 | 27.2 (371/1362) (24.9–29.6) | 37.4 (443/1186) (34.6–40.1) | 40.9 (438/1070) (38.0–43.9) | 44.9 (191/425) (40.2–49.7) |
| DAS28-CRP ≤ 3.2 | 40.8 (553/1355) (38.2–43.4) | 50.7 (600/1183) (47.9–53.6) | 55.0 (585/1064) (52.0–58.0) | 57.6 (238/413) (52.9–62.4) |
| DAS28-CRP < 2.6 | 24.6 (334/1355) (22.4–26.9) | 34.7 (411/1183) (32.0–37.5) | 39.9 (425/1064) (37.0–42.9) | 40.9 (169/413) (36.2–45.7) |
| Change from baseline, mean (SE) (95% CI) | ||||
| DAS28-CRP ≤ 3.2 | −2.65 (0.03) (−2.71 to −2.58) | −2.94 (0.04) (−3.01 to −2.86) | −3.09 (0.04) (−3.17 to −3.00) | −3.24 (0.07) (−3.38 to −3.11) |
| Improvement from baseline, mean (SE) % (95% CI) | ||||
| CRP, mg/dl | 15.04 (7.80) (−0.27 to 30.35) | 9.70 (11.58) (−13.03 to 32.43) | 4.21 (7.90) (−11.28 to 19.70) | −7.05 (19.29) (−44.97 to 30.88) |
ACR20: American College of Rheumatology 20% improvement criteria; DAS28-CRP: 28-joint count Disease Activity Score using C-reactive protein; LTE: longterm extension.